Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease

Abstract

Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.

Compliance with pharmacological treatment among patients after minimally invasive coronary bypass grafting

“…The patients who experienced repeat revascularization with PCI more frequently used antiplatelet drugs, which can probably be attributed to more careful approach of attending physicians alert to severe complications, such as stent thrombosis. It is in line with current recommendation as the treatment reduces risk of stent occlusion and subsequent risk of all cardiovascular events, including death which was confirmed in several studies [21]. Also, we found a correlation between ingestion of antiplatelet agents and BB, and the need for readmission.…”

“…Also, we found a correlation between ingestion of antiplatelet agents and BB, and the need for readmission. Compliant individual less frequently experienced hospitalization compared to patients indifferent to pharmacotherapy, hence we assume that pharmacological interventions help improve patients' outcome and reduce costs for the healthcare system [21][22][23][24][25][26]. Although our study failed to demonstrate a statistically significant link between patients' clinical features and drug compliance, we managed to denote considerable prevalence of the issue of therapeutic non-adherence and its clinical implications.…”

The Use of Anti-Platelet and/or Anticoagulant Agents in the Prevention of Large Vessel Vasculitis-Associated Ischemic Complications: A Meta-Analysis

“…Low dose ASA has been observed to inhibit thrombosis in cardiovascular disease by inhibiting platelet activation and aggregation as well as improving endothelial dysfunction [30]. This protective mechanism may explain ASA's benefits in TAK as thromboxane B2 levels have been observed to increase in the affected limb of TAK patients and decrease in response to ASA treatment [31]- [33].…”

New antithrombotic therapies and complementary and alternative medicine (CAM): Chartering into unknown territory

“…Aspirin, which has long been the bedrock of antiplatelet therapy in patients with acute coronary syndromes (ACS) [6], is one of the most widely used medical treatments worldwide with millions of patients taking low-dose aspirin on a daily basis [7]. Clopidogrel, a newer antiplatelet agent listed on the PBS since 2009, is a more potent platelet inhibitor than aspirin and has been shown to be more effective in ACS when combined with aspirin when compared with aspirin therapy alone [8,9].…”